Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Cyltezo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
VOLTAIRE-X data showed that switching several times between Cyltezo® (adalimumab-adbm) and Humira® (adalimumab) resulted in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate-to-severe chronic plaque psoriasis.